Adrenal Cancer Overview

Save information for later
Sign Up

Learn About Adrenal Cancer

What is the definition of Adrenal Cancer?
Adrenal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the adrenal glands (small glands that sit above each kidney). In most cases, the underlying cause of the condition is unknown. However, certain genetic conditions such as multiple endocrine neoplasia type 2, Li-Fraumeni syndrome, Von Hippel-Lindau syndrome, neurofibromatosis type I, and Carney complex are associated with an increased risk of developing adrenal tumors and cancer.
What are the alternative names for Adrenal Cancer?
  • Adrenal cancer
What are the different types of Adrenal Cancer?

Common conditions include: Adrenal Gland Adenoma, Pheochromocytoma

Who are the top Adrenal Cancer Local Doctors?
Dr. Anand Vaidya
Endocrinology
Dr. Anand Vaidya
Endocrinology

Brigham And Womens Physicians Organization Inc

221 Longwood Ave, 
Boston, MA 
 (2.0 mi)
617-732-5500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anand Vaidya is an Endocrinologist in Boston, Massachusetts. Dr. Vaidya and is rated as an Elite provider by MediFind in the treatment of Adrenal Cancer. His top areas of expertise are Hyperaldosteronism, Adrenal Cancer, Adrenal Gland Adenoma, Thyroidectomy, and Gastric Bypass.

Dr. Frederick T. Drake
General Surgery
Dr. Frederick T. Drake
General Surgery

Boston University General Surgical Associates, Inc.

1 Boston Medical Ctr Pl, 
Boston, MA 
 (2.7 mi)
617-638-8605
Experience:
17+ years
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Frederick Drake is a General Surgeon in Boston, Massachusetts. Dr. Drake has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Adrenal Cancer. His top areas of expertise are Appendicitis, Hyperparathyroidism, Gallbladder Adenocarcinoma, Appendectomy, and Parathyroidectomy. Dr. Drake is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Matthew H. Kulke
Oncology
Dr. Matthew H. Kulke
Oncology

Evans Medical Foundation Inc

1 Boston Medical Ctr Pl, 
Boston, MA 
 (2.7 mi)
857-654-1000
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Matthew Kulke is an Oncologist in Boston, Massachusetts. Dr. Kulke and is rated as an Experienced provider by MediFind in the treatment of Adrenal Cancer. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Carcinoid Syndrome, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Liver Embolization. Dr. Kulke is currently accepting new patients.

View All Doctors
What are the latest Adrenal Cancer Clinical Trials?
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Drug
Study Phase: Phase 1

Background: Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal glands, and other areas of the body. Many of these cancers have a high risk of relapse and a low chance of survival. Better treatments are needed.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Who is this study for: Patients with Melanoma
Enrollment Status: Recruiting
Publish Date: February 24, 2025
Intervention Type: Drug, Procedure, Biological, Other
Study Drugs: Cyclophosphamide, Fludarabine Phosphate, IL13Ralpha2-Specific Hinge-Optimized 4-1BB-co-Stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Recombinant Interleukin-2
Study Phase: Phase 1

Summary: This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center